Digital Technology in Clinical Trials

Session Chair(s)

The rapid adoption of decentralized trials and research is a silver lining of the coronavirus pandemic. Stakeholders across the medical product development continuum moved to integrate decentralized approaches to maintain continuity and respond to the demands of COVID-19. Many organizations developed processes and practices to integrate new technology, while patients and investigators adapted to new ways to interacting, receiving and delivering care and collecting data. As we emerge from the pandemic, what approaches should be retained and how can our community implement process and procedure that is fit for purpose, taking into account the needs and preferences of all stakeholders?

Learning Objective :

• Demonstrate how robust clinical trial processes can be developed and optimised ensuring introduction of new technology into decentralised clinical trials to allow patient centric data collection
• Recognize the impact of decentralization on patients – explain how choice and optionality in clinical trials can be incorporated
• Identify remaining challenges to the adoption of decentralized approaches and recognize ways of overcoming barriers

Speaker(s)